Sigma-Tau Research, Inc.

Quick facts

Phase 3 pipeline

• PLC · Oncology
  PLC is a drug that targets the PI3K/AKT pathway.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sigma-Tau Research, Inc. portfolio CI brief
• Sigma-Tau Research, Inc. pipeline updates RSS